newssun
ANNOYING 
Weather Updates

Baxter 3Q earnings edge up, sales flat

Baxter International Inc. said its net income fell 6 percent first quarter charges related its pending purchase dialysis product maker

Baxter International Inc. said its net income fell 6 percent in the first quarter on charges related to its pending purchase of dialysis product maker Gambro AB.

storyidforme: 38680467
tmspicid: 12488733
fileheaderid: 4850234

Updated: November 20, 2012 10:53AM



DEERFIELD — Baxter International Inc. said its net income edged up 1 percent in the third quarter, while net sales were flat.

The company earned $583 million in the quarter, up from $576 million in the year-ago period. Earnings per share were $1.06, up five percent.

Net sales were $3.48 billion.

Its BioScience business generated $1.5 billion in sales similar to the prior year. Excluding the impact of foreign currency, revenues rose 5 percent driven by double-digit growth in the U.S. across all key product categories and robust growth in demand for its hemophilia medicine Advate, Baxter said.

Baxter’s Medical Products Business generated $2 billion in sales. Excluding the impact of foreign currency, sales rose 4 percent amid strong growth of injectable drugs, anesthesia products and nutritional therapies.

The company said it expects fourth quarter earnings per share of $1.24 to $1.27 before special items and sales growth of 5 percent to 6 percent, excluding foreign exchange.

Baxter tightened its full-year earnings per share guidance range to $4.51 to $4.54. It said it continues to expect sales growth of 4 percent to 5 percent.



© 2014 Sun-Times Media, LLC. All rights reserved. This material may not be copied or distributed without permission. For more information about reprints and permissions, visit www.suntimesreprints.com. To order a reprint of this article, click here.